Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide

Sharma, 2007, Epidermal growth factor receptor mutations in lung cancer, Nat Rev Cancer, 7, 169, 10.1038/nrc2088

Yewale, 2013, Epidermal growth factor receptor targeting in cancer: A review of trends and strategies, Biomaterials, 34, 8690, 10.1016/j.biomaterials.2013.07.100

Hynes, 2005, ERBB receptors and cancer: the complexity of targeted inhibitors, Nat Rev Cancer, 5, 341, 10.1038/nrc1609

Barker, 2001, Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer, Bioorg Med Chem Lett, 11, 1911, 10.1016/S0960-894X(01)00344-4

Brown, 2005, Erlotinib in the treatment of non-small cell lung cancer, Expert Rev Anticancer Ther, 5, 767, 10.1586/14737140.5.5.767

Pao, 2005, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med, 2, 225, 10.1371/journal.pmed.0020073

Xu, 2010, Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib, Cancer Biol Ther, 9, 572, 10.4161/cbt.9.8.11881

Yun, 2008, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP, Proc Natl Acad Sci USA, 105, 2070, 10.1073/pnas.0709662105

Yu, 2013, Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers, Clin Cancer Res, 19, 2240, 10.1158/1078-0432.CCR-12-2246

Li, 2008, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models, Oncogene, 27, 4702, 10.1038/onc.2008.109

Cross, 2014, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer, Cancer Discov, 4, 1046, 10.1158/2159-8290.CD-14-0337

Goss, 2016, Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study, Lancet Oncol, 17, 1643, 10.1016/S1470-2045(16)30508-3

Mok, 2017, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, New Engl J Med, 376, 629, 10.1056/NEJMoa1612674

Thress, 2015, Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, Nat Med, 21, 560, 10.1038/nm.3854

Bondeson, 2015, Catalytic in vivo protein knockdown by small-molecule PROTACs, Nat Chem Biol, 11, 611, 10.1038/nchembio.1858

Corson, 2008, Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One, ACS Chem Biol, 3, 677, 10.1021/cb8001792

Toure, 2016, Small-Molecule PROTACS: New Approaches to Protein Degradation, Angew Chem Int Ed Engl, 55, 1966, 10.1002/anie.201507978

Schneekloth, 2008, Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics, Bioorg Med Chem Lett, 18, 5904, 10.1016/j.bmcl.2008.07.114

Rodriguez-Gonzalez, 2008, Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer, Oncogene, 27, 7201, 10.1038/onc.2008.320

Zorba, 2018, Delineating the role of cooperativity in the design of potent PROTACs for BTK, Proc Natl Acad Sci USA, 115, E7285, 10.1073/pnas.1803662115

Sun, 2018, PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies, Cell Res, 28, 779, 10.1038/s41422-018-0055-1

Hu, 2019, Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER), J Med Chem, 62, 1420, 10.1021/acs.jmedchem.8b01572

Delport, 2019, Inducing the degradation of disease-related proteins using heterobifunctional molecules, Molecules, 24, 3272, 10.3390/molecules24183272

Zhou, 2018, Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression, J Med Chem, 61, 462, 10.1021/acs.jmedchem.6b01816

Raina, 2016, PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer, Proc Natl Acad Sci USA, 113, 7124, 10.1073/pnas.1521738113

Mullard, 2019, Arvinas's PROTACs pass first safety and PK analysis, Nat Rev Drug Discov, 18, 895

Burslem, 2018, The advantages of targeted protein degradation over inhibition: an RTK case study, Cell Chem Biol, 25, 10.1016/j.chembiol.2017.09.009

Zhang, 2020, Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC), Eur J Med Chem, 189, 112061, 10.1016/j.ejmech.2020.112061

Cheng, 2020, Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders, J Med Chem, 63, 1216, 10.1021/acs.jmedchem.9b01566

Zhang, 2017, Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants, Eur J Med Chem, 135, 12, 10.1016/j.ejmech.2017.04.036